

U-CyTech BV

Yalelaan 48 3584 CM Utrecht The Netherlands P +31.30.253 5960 F +31.30.253 9344 INFO@ucytech.com www.ucytech.com

Data sheet Human IL-4 ELISPOT antibody pair; 20-plate format

Cat. No.: CT642-20

Coating antibodies (1 vial)

Product: Monoclonal antibody to human interleukin 4 (IL-4)

Isotype: Mouse IgG₁

Production: In vitro using serum free medium

Purification: Ion exchange chromatography

Contents: Each vial contains sufficient material for coating of twenty 96-well ELISPOT plates

Buffer: Prior to lyophilization: 1.0 ml PBS + 125 mM trehalose

Application: Coating antibody in an ELISPOT system

Reconstitution: Dissolve the contents of the vial by injection of 1.0 ml distilled water into the vial

and dilute 100 times in PBS. The total amount of one vial is sufficient for twenty

96-well ELISPOT plates (1920 determinations; 50 µl/well).

Detection antibodies (1 vial)

Product: Biotinylated monoclonal antibody to human interleukin 4 (IL-4)

Isotype: Rat IgG₁

Production: In vitro using serum free medium

Purification: Protein G-affinity chromatography

Labeling: With Biotin-7-NHS (N-hydroxysuccinimide)

Contents: Each vial contains sufficient material for twenty 96-well ELISPOT plates

Buffer: Prior to lyophilization: 2.0 ml PBS + 1% BSA + 125 mM trehalose

Application: Detection antibody in an ELISPOT system

Reconstitution: Dissolve the contents of the vial by injection of 2.0 ml distilled water into the vial

and dilute 100 times in Dilution buffer (see Technical Data Sheet). The total amount of one vial is sufficient for twenty 96-well ELISPOT plates (1920

determinations; 100 μ I/weII).

General

Specificity: Validated for detecting human IL-4

Sterility: Membrane filtered (0.2 µm)

Stability: The lyophilized products are stable for at least one year at 4°C (expiry date is

indicated on the vials).

After reconstitution, the antibodies are stable for several months at 4°C (if kept

sterile) or for minimal one year at -20°C.

References: Arif, S. et al. 2004. J. Clin. Invest. 113: 451-463

Van Besouw, N.M. *et al.* 2002. Transpant. Proc. 34: 2942-2943 Kloosterboer, F.M. *et al.* 2004. Hum. Immunol. 65: 328-339 Martin, S. *et al.* 2001. N. Engl. J. Med. 345: 1036-1040

Raz, I. et al. 2001. Lancet 358: 1749-1753

Zanone, M.M. et al. 2010. J. Clin. Endocrinol. Metab. 95: 3788-3797



For research use only